Lovastatin
Cat.No:IL0220 Solarbio
CAS:75330-75-5
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:HPLC≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Metabolic Enzyme & Protease >
LovastatinCAS:75330-75-5
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:HPLC≥98%
Appearance:White to off-white Solid
Qty:
Size:
CAS | 75330-75-5 |
Name | Lovastatin |
Molecular Formula | C24H36O5 |
Molecular Weight | 404.54 |
Solubility | Soluble in DMSO ≥4mg/mL |
Purity | HPLC≥98% |
Appearance | White to off-white Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
EC | EINECS 616-212-7 |
MDL | MFCD00072164 |
SMILES | O=C([C@@H](C)CC)O[C@@H]1[C@@]([C@H]2CC[C@@H](OC3=O)C[C@H](C3)O)([H])C(C=C[C@@H]2C)=C[C@H](C)C1 |
InChIKey | PCZOHLXUXFIOCF-BXMDZJJMSA-N |
InChI | InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1 |
PubChem CID | 53232 |
Target Point | HMG-CoA Reductase (HMGCR) |
Passage | Metabolic Enzyme&Protease |
Background | Lovastatin is a cell-permeable HMG-CoA reductase inhibitor for cholesterol reduction. |
Biological Activity | Lovastatin是一种用于降低胆固醇的细胞渗透性的 HMG-CoA还原酶抑制剂。[1-4] |
In Vitro | 洛伐他汀是无活性的内酯前药,必须通过化学或酶促转化为其二羟基开环酸形式,以引发抑制活性。羟基酸形式的洛伐他汀是一种特别有效的肝HMG CoA还原酶竞争性抑制剂[1]。洛伐他汀除抗其抗胆固醇外,在骨质疏松症,神经变性,类风湿性关节炎,抗真菌药等领域具有多种应用,据报道还可减少肺癌细胞,乳腺癌(MCF-7),肝癌(HepG2)的增殖。 。洛伐他汀治疗对HeLa细胞显示出显著的剂量依赖性细胞毒作用,IC50值为160μg/ mL。洛伐他汀可有效加速羟自由基清除活性(54.06%),IC50为3601μg/ mL [2]。 |
In Vivo | 洛伐他汀是一种无活性的内酯,在肝脏中水解成活性的f3-羟基酸形式。该主要代谢物是酶HMG-CoA还原酶的抑制剂。 Ki为1 nM。洛伐他汀及其β-羟基酸代谢物与人血浆蛋白高度结合。洛伐他汀穿过血脑和胎盘屏障[3]。洛伐他汀可显著降低含载脂蛋白B的脂蛋白,尤其是低密度脂蛋白胆固醇,血浆甘油三酯含量较低,高密度脂蛋白胆固醇含量略有增加[4]。 |
Cell Experiment | 用洛伐他汀(0,5,10,20,40,80,160,320μg/ mL)处理Hela细胞24小时。用培养基处理的细胞用作阴性对照。使用基于MTT的比色测定法测量细胞活力[2]。 |
Data Literature Source | [1]. Alberts AW,et al. Discovery,biochemistry and biology of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):10J-15J. [2]. Bhargavi S,et al. Purification of Lovastatin from Aspergillus terreus (KM017963) and Evaluation of its Anticancer and Antioxidant Properties. Asian Pac J Cancer Prev. 2016;17(8):3797-803. [3]. Frishman WH,et al. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989 Mar;73(2):437-48. [4]. Tobert JA,et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. |
Unit | Bottle |
Specification | 10mg 10mM*1mL in DMSO 50mg |
是一种用于降低胆固醇的细胞渗透性的 HMG-CoA还原酶抑制剂。
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling
Click to check >>Author:Gao Jian, Hu Jifen, Yu Fang, Wang Chunlin, Sheng Danmei, Liu Wuling, Hu Anling, Yu Kunling, Xiao Xiao, Kuang Yi, Zacksenhaus Eldad, Gajendran Babu, Ben-David Yaacov
IF:4.6380
Publish_to:BMC CANCER
PMID:37016335